Early results from new PD-1 targeted immune therapy
Dr Suzanne Topalian - Johns Hopkins University School of Medicine, Baltimore, US...
Early results from new PD-1 targeted immune therapy ( Dr Suzanne Topalian - Johns Hopkins University School of Medicine, Baltimore, USA )
2 Jun 2012
New study asks patients preference on kidney cancer treatment
Dr Bernard Escudier - Institut Gustave Roussy, Paris, France
New study asks patients preference on kidney cancer treatment ( Dr Bernard Escudier - Institut Gustave Roussy, Paris, France )
2 Jun 2012
Relapse and survival of adolescent and young adult leukaemia patients
Dr Eric Larsen - Maine Children’s Cancer Program, Scarborough, USA
Relapse and survival of adolescent and young adult leukaemia patients ( Dr Eric Larsen - Maine Children’s Cancer Program, Scarborough, USA )
2 Jun 2012
Adding bevacizumab to chemotherapy for platinum-resistant ovarian cancer improve...
Dr Eric Pujade-Lauraine - Université Paris Descartes, France
Adding bevacizumab to chemotherapy for platinum-resistant ovarian cancer improves progression-free survival ( Dr Eric Pujade-Lauraine - Université Paris Descartes, France )
2 Jun 2012
The OECI and EurocanPlatform
Prof Wim van Harten – The Netherlands Cancer Institute, Amsterdam
The OECI and EurocanPlatform ( Prof Wim van Harten – The Netherlands Cancer Institute, Amsterdam )
21 May 2012
Problems in the structure of clinical trials
Prof Thomas Tursz – Institut Gustave Roussy, Paris, France
Problems in the structure of clinical trials ( Prof Thomas Tursz – Institut Gustave Roussy, Paris, France )
21 May 2012
Heterogeneity of global cancer outcomes
Prof Reinhard Busse – Technische Universitat, Berlin, Germany
Heterogeneity of global cancer outcomes ( Prof Reinhard Busse – Technische Universitat, Berlin, Germany )
18 May 2012
New approaches to personalised medicine
Prof Jens Ricke – Otto-Von-Guericke-University, Magdeburg, Germany
New approaches to personalised medicine ( Prof Jens Ricke – Otto-Von-Guericke-University, Magdeburg, Germany )
18 May 2012
Recent developments in neoadjuvant therapy
Prof Gunter Von Minckwitz – German Breast Group, Neu-Isenburg, Germany
Recent developments in neoadjuvant therapy ( Prof Gunter Von Minckwitz – German Breast Group, Neu-Isenburg, Germany )
17 May 2012
Highlights and goals of IMPAKT 2012
Prof Martine Piccart – Jules Bordet Institute, Brussels, Belgium
Highlights and goals of IMPAKT 2012 ( Prof Martine Piccart – Jules Bordet Institute, Brussels, Belgium )
17 May 2012
PI3K and the heterogeneity of small tumour breast cancer
Dr Sherene Loi – Jules Bordet Institute, Brussels, Belgium
PI3K and the heterogeneity of small tumour breast cancer ( Dr Sherene Loi – Jules Bordet Institute, Brussels, Belgium )
17 May 2012
Molecularly characterising triple negative breast cancer
Prof Jorge Reis-Filho – Jules Bordet Institute, Brussels, Belgium
Molecularly characterising triple negative breast cancer ( Prof Jorge Reis-Filho – Jules Bordet Institute, Brussels, Belgium )
17 May 2012